© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
(Reuters) – The U.S. Food and Drug Administration said on Wednesday Eli Lilly (NYSE:) and Co’s COVID-19 drug bebtelovimab is not currently authorized for emergency use in the country as it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Credit: Source link